Action receives UK MHRA clearance for hESC-derived RPE cell trial for Stargardt’s Macular Dystrophy Advanced Cellular Technology, Inc. ;, a innovator in the field of regenerative medicine, today that it all has received clearance from the U announced vardénafil .K. Medicines and Healthcare products Regulatory Company to begin treating patients as part of a Phase 1/2 clinical trial for Stargardt’s Macular Dystrophy using retinal pigment epithelium produced from human being embryonic stem cells . ACT received similar authorization from the Gene Therapy Advisory Committee , which has responsibility for the ethical oversight of proposals to carry out medical trials concerning gene or stem cell therapies in the U.K.
Funding will support Company efforts to progress two clinical-stage pipeline assets targeting rare central and muscular nervous program disorders. The financing will also be used to expand the AMO Pharma pipeline through acquisition of extra development-stage products. ‘Following our successful acquisition of two promising substances, our funding with Woodford provides us with the assets we have to continue to rapidly progress our clinical development applications while also positioning us to further increase our pipeline. ‘We are specially pleased that the group at Woodford, a worldwide leader in life technology investments, has identified the strong potential for success in both our resources and our business design at AMO Pharma.’ In early 2016, AMO Pharma plans to initiate a Phase II medical trial for the business's lead item candidate, AMO-02, in the treatment of a severe type of myotonic dystrophy referred to as DM1 or Steinert's disease.